The race for the next Ozempic is on

Two new studies indicate that people who take medications containing the substance Semaglutide – which is found in the popular diabetes medication Ozempic, among other things – are at an increased risk of developing the eye disease Naion. The European Medicines Agency's Safety Committee PRAC has therefore begun a review of medications such as Ozempic, the Swedish Medicines Agency writes...

Drugs like Ozempic could also curb addictions — but they might boost other health risks, study suggests

Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and other medications like it have a host of other potential health benefits beyond obesity, but could also bring increased risk of other conditions.

Now, according to American research, it appears that slimming injections can solve dozens of health problems such as cardiovascular diseases and dementia. But beware: they can also cause other ailments.

The race for the next Ozempic is on

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to crown any winners in the race for the next generation of anti-obesity treatments.Read more...

Ozempic increases risk of arthritis and stomach issues, study finds

While Ozempic has been praised for its ability to induce weight loss and treat a range of health conditions, it could also lead to an increased risk of arthritis, gastrointestinal disorders and other issues, according to new research.The US study published in the Nature Medicine journal highlighted that drugs such as Ozempic, called glucagon-like peptide-1 (GLP-1) receptor agonists, can treat more than just obesity but have potential positive an…

Sweeping study finds 42 health conditions Ozempic can improve – and 19 it makes worse

Weight-loss drugs such as Ozempic can help people to lose more than a fifth of their body weight and have been linked to a range of other health benefits, but also some concerns.